Our Advisory Board includes thought leaders, industry experts and executives with diverse and deep experience across a range of disciplines and industries - from medicine and pharmacology to medical devices and regulatory affairs. Our Advisors provide invaluable perspectives and insights on our research projects and our companies, helping inform and shape our strategy and future direction. The following are advisors to InCube Labs and/or InCube Ventures.
- Dennis Ausiello, M.D., Professor, Harvard Medical School; Chief of Medicine, Massachusetts General Hospital
Dr. Ausiello has served as Jackson Professor of Clinical Medicine at Harvard Medical School and Chief of Medicine at Massachusetts General Hospital since 1996. Dr. Ausiello's experience includes President of the Association of American Physicians in 2006, Member of the Institute of Medicine and a Fellow of the American Academy of Arts and Sciences, Director of TARIS BioMedical, Inc. Currently, Dr. Ausiello serves as a Director on Pfizer's Board since December 2006; he is also a member of Pfizer's Audit Committee, Corporate Governance Committee and Science and Technology Committee.
- Fabrizio Bonanni, Former Executive at Amgen and Baxter
Dr. Fabrizio Bonanni retired in 2013 from his position as executive vice president at Amgen Inc. In his 14 years with the company, he served as senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and finally as EVP Operations, overseeing the company's global production and supply chain activities as well as Quality, Process Development, Drug Delivery Devices, and Engineering.
While at Amgen, Bonanni served as a Trustee of the California Science Center, of the Los Angeles Museum of Contemporary Art, and of the Science Technology and Research Trust of Puerto Rico. He also served on the executive committee of the Board of BIO, the Biotechnology Industry Association.
Previously, he was corporate vice president, Regulatory and Clinical Affairs and corporate vice president, Quality System for Baxter International Inc., a company he joined in 1974. At Baxter, Bonanni spent half of his career in international operations, including an eight-year assignment as vice president, Quality and Regulatory Affairs at the company's European headquarters in Brussels, Belgium.
Bonanni earned his doctorate in chemistry, magna cum laude, mention of honor, from the University of Florence and did postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management, and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration.
Currently, Dr. Bonanni is a member of the Board of the Stevanato Group, an Italian company developing and manufacturing high quality primary containers for the bio-pharma industry as well as manufacturing engineering solutions for glass container manufacturers.
- Kathleen A. Buto, Public Policy & Global Health Policy Expert
Kathy Buto is currently an independent consultant, focused on health policy issues. She serves as a Commissioner, Medicare Payment Advisory Commission, which advises Congress and the Administration on Medicare payment to health plans and providers. Ms. Buto retired in March 2013 as Vice President, Global Health Policy, Government Affairs, at Johnson & Johnson, where she was responsible for helping to identify opportunities for J&J to take leadership in shaping health care policy globally. She managed a team that included physicians, economists, and health policy analysts in the U.S., Europe, and Asia Pacific and addressed issues that included expanding access to health services for populations in the emerging markets, interacting with health care authorities, and promoting prevention services globally.
Prior to joining J&J, Kathy was a senior health adviser at the Congressional Budget Office, helping to develop the cost models for the Medicare drug benefit. Before that, she spent more than 18 years in senior positions at the Health Care Financing Administration, now called the Centers for Medicare & Medicaid Services. In these positions, she headed the policy, reimbursement, research, and coverage functions for the agency, as well as co-leading Medicare’s fee-for-service and managed care operations.
Kathy was the recipient of 5 Presidential Rank Awards and the 1999 Public Service Award while in government and several Standards of Leadership Awards and New Jersey’s Women and Industry Award in 2010, while at Johnson & Johnson. She received her Bachelor of Arts from Douglass College and her Masters in Public Administration from Harvard University.
- Duke Collier, CEO of Arsenal Medical; Senior Advisor, Polaris Venture Partners
Duke Collier currently serves as CEO of Arsenal Medical and is a Senior Advisor with Polaris Ventures. Prior to his role at Polaris, Mr. Collier was Executive Vice President at Genzyme where he managed and built several of Genzyme's newer businesses, including its oncology and cardiovascular business units. During his tenure at Genzyme, Mr. Collier was responsible for building the biosurgery business and oversees the company's efforts in multiple sclerosis and other immune disorders. He has also led some of Genzyme's significant acquisitions and the formation of MG Biotherapeutics, Genzyme's joint venture with Medtronic Inc., which is focused on cardiac cell therapy.
Mr. Collier has more than 30 years of experience in healthcare. From 1991-1995, he was president of Vitas Healthcare Corp., the largest provider of hospice services in the United States. Between 1981 and 1991, Mr. Collier was a partner at Hogan & Hartson law firm in Washington, D.C. He served as deputy administrator for the Health Care Financing Administration (HCFA) in Baltimore, MD, during the Carter Administration. From 1977 to 1979, Mr. Collier was deputy administrator of the New York State offices of Health Systems Management. He was an associate at Covington and Burlington law firm in Washington, D.C., from 1974 to 1977. Mr. Collier began his legal career in Washington as a clerk for the U.S. Court of Appeals.
Mr. Collier sits on the boards of Newton-Wellesley Hospital, Pervasis Therapeutics, and Beacon Hospice, and is a member of the Director's Council of the MIT Center for Cancer Research. He is also a Senior Advisor to Polaris Venture Partners. He earned a B.A. at Yale University and a J.D. at the University of Virginia Law School.
- Bruce Given, M.D., CEO, Leonardo Biosystems
Dr. Given is CEO of Leonardo Biosystems, serves as a Healthcare Products Consultant as the Principal of Bruce Given Consulting and is Chairman of the Board for ICON, plc. (Nasdaq: ICLR). Until June of 2007, Dr. Given served as President and Chief Executive Officer and as a member of the Board of Directors of Encysive Pharmaceuticals, which he joined in 2002. Prior to joining Encysive Pharmaceuticals, he was with Johnson & Johnson for 9 years, serving in several capacities including as President, International, Ortho-Clinical Diagnostics and as Group Vice President, Head of U.S. Marketing & Sales, Research & Development for Janssen Pharmaceutica. He has held various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute and Schering-Plough Corporation. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago.
Dr. Given obtained his bachelor of sciences degree from Colorado State University, graduating Phi Beta Kappa. He received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women's Hospital in Boston, where he was a Clinical Fellow at Harvard Medical School. He is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications.
In addition to his work with Leonardo and ICON, Dr.Given serves on the Boards of Directors for Calando Pharmaceuticals, for BioHouston, where he is Secretary of the Executive Committee of the Board and the Texas Life Science Center. He is a member of the CPRIT Commercialization Committee, a member of the inCube Scientific Advisory Board, served on the Technology Review Committee of MD Anderson Medical Center, and is past Chairman of the Rider University Scientific Advisory Board.
- Peter Barton Hutt, Senior Counsel, Covington & Burling LLP
Peter Barton Hutt is a Partner specializing in food and drug law in the Washington, D.C. law firm of ovington & Burling. He served as Chief Counsel for the FDA from 1971-1975 and is the co-author of a casebook used to teach food and drug law throughout the country.
Mr. Hutt currently serves on the Boards of Directors of several public and privately-held biotechnology companies, including CV Therapeutics, Inc. and Cognetix, Inc., and venture capital advisory boards, including Polaris Venture Partners and the Sprout Group. He has previously served as a director of other companies, including IDEC Pharmaceuticals Corporation (now Biogen IDEC Inc.) during its development of Rituxan®.
Mr. Hutt has served on many advisory committees including the Advisory Committee to the Director of the National Institutes of Health (NIH), the NIH Advisory Committee to Review the Guidelines for Recombinant DNA Research, and five Office of Technology Assessment advisory panels.
Washingtonian magazine has named Mr. Hutt one of Washington D.C.'s 50 best lawyers (out of more than 40,000) and one of Washington D.C.'s 100 most influential people. The National Law Journal has named him one of the 40 best health care lawyers in the United States and the European Counsel has called him the best FDA regulatory specialist in Washington, D.C. Mr. Hutt graduated from Yale University and Harvard Law School and earned a Master of Laws degree in Food and Drug Law from New York University Law School.
- Michael A. Mussallem, Chairman and CEO, Edwards Lifesciences
Michael A. Mussallem, age 56, has been chairman and CEO of Edwards Lifesciences, Inc. since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mr. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor's degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Indiana.
- Bill Ringo, Former Executive Pfizer and Lilly
Mr. Ringo served as the Senior Vice President Strategy and Business Development at Pfizer from 2008-2010. Mr. Ringo currently serves as a Senior Advisor to Barclays Capital and executive in residence at Sofinnova. In addition, Mr. Ringo serves as Chairman of the Board for Sangamo BioSciences, which is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification, and holds a Board seat for Onyx Pharmaceuticals, Inc., a biopharmaceutical company committed to improving the lives of people with cancer. Mr. Ringo also serves on the Board of Directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region.
Prior to joining Pfizer, Mr. Ringo served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From 2004 to 2006, he was President and CEO of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which purchased Abgenix in 2006.
Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure there he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. Mr. Ringo holds a B.S. in Business Administration and an M.B.A. from the University of Dayton.